FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Ipamorelin

NNC 26-0161

Growth Hormone Secretagogues

Ipamorelin is a highly selective pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor to stimulate pulsatile GH release from the anterior pituitary. Developed by Novo Nordisk in the 1990s, it is distinguished from other GHRPs by its remarkable selectivity, producing GH release without significantly affecting cortisol, prolactin, or aldosterone levels. It is considered the most well-tolerated GHRP available and is a cornerstone of modern GH optimization research protocols.

작용 메커니즘

Selective growth hormone secretagogue receptor (GHSR) agonist. Stimulates pituitary GH release with minimal effect on cortisol, prolactin, or ACTH. One of the most selective ghrelin mimetics available, producing clean GH pulses without appetite stimulation.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 100-300mcg 2-3 times daily via subcutaneous injection. Best administered on an empty stomach. Often combined with CJC-1295 for synergistic GH release. Cycles of 8-16 weeks.

연구 노트

Clinical Research Status

Ipamorelin completed Phase 2 clinical trials for post-operative ileus (gut motility recovery) but was not advanced to approval. Published human studies confirm dose-dependent GH release with minimal effect on other pituitary hormones. It remains widely used in clinical research and anti-aging medicine despite lacking FDA approval for any indication.

Key Published Findings

Studies demonstrate that Ipamorelin produces GH release comparable to GHRP-6 and GHRP-2 at equivalent doses without the cortisol and prolactin elevation seen with those compounds. Research shows it does not significantly stimulate appetite (unlike GHRP-6 and hexarelin) due to weaker ghrelin receptor activation in appetite centers. Clinical trials documented improved bowel recovery time in post-surgical patients.

Safety Profile

Ipamorelin has the cleanest side effect profile among all GHRPs, with minimal reports of water retention, hunger stimulation, or cortisol elevation at standard doses. Transient headache, flushing, and mild dizziness may occur in the first 1-2 weeks of use. No significant adverse cardiovascular or metabolic effects have been documented in published trials at therapeutic doses.

Drug Interactions & Contraindications

Should not be used concurrently with somatostatin or its analogs. Caution advised when combining with insulin or insulin secretagogues due to GH's diabetogenic effects. Contraindicated in active malignancy and untreated pituitary tumors. May reduce efficacy of glucocorticoids through GH-mediated cortisol suppression at high doses.

Comparison to Related Compounds

Compared to GHRP-6, Ipamorelin produces equivalent GH release without significant hunger or cortisol elevation. Compared to GHRP-2, it has slightly lower maximal GH output but substantially fewer side effects. Hexarelin produces the highest GH response among GHRPs but causes significant cortisol/prolactin release and desensitizes within weeks, making Ipamorelin preferred for longer protocols.

Community Observations

Standard research dosing is 100-300mcg subcutaneously 1-3 times daily, typically combined with Modified GRF(1-29) at equal doses for synergistic GH release. Most commonly administered before sleep to augment the natural nocturnal GH pulse. Users consistently report improved sleep quality, recovery, and gradual body composition improvements with minimal side effects over 3-6 month protocols.

반감기

~2 hours

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 24 months.

재조성된 상태

Refrigerate 2-8C. Use within 21 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

NNC 26-0161

자주 묻는 질문

Ipamorelin란 무엇인가요?

Ipamorelin is a highly selective pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor to stimulate pulsatile GH release from the anterior pituitary. Developed by Novo Nordisk in the 1990s, it is distinguished from other GHRPs by its remarkable selectivity, producing GH release without significantly affecting cortisol, prolactin, or aldosterone levels. It is considered the most well-tolerated GHRP available and is a cornerstone of modern GH optimization research protocols.

Ipamorelin는 어떻게 작용하나요?

Selective growth hormone secretagogue receptor (GHSR) agonist. Stimulates pituitary GH release with minimal effect on cortisol, prolactin, or ACTH. One of the most selective ghrelin mimetics available, producing clean GH pulses without appetite stimulation.

Ipamorelin의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Ipamorelin의 반감기는 얼마인가요?

~2 hours

Ipamorelin의 다른 이름은 무엇인가요?

NNC 26-0161

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기